Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NKG2D-41BB-CD3z CAR-NKAE cells
- Development stage
- Preclinical
- Lead developer
- Hospital Universitario 12 de Octubre
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
NKG2D-41BB-CD3z CAR-NKAE cells are an experimental cell therapy consisting of activated and expanded natural killer (NKAE) cells transduced with a second-generation chimeric antigen receptor (CAR) targeting NKG2D ligands (NKG2DL). The CAR construct incorporates the extracellular domain of the natural killer group 2 member D (NKG2D) receptor, a CD8a hinge region, and the intracellular signaling domains of 4-1BB (CD137) and CD3z. This therapy is designed to target and eliminate tumor cells, such as acute myeloid leukemia (AML) blasts, which overexpress stress-induced NKG2D ligands (including MICA, MICB, and ULBP1-6), while minimizing graft-versus-host disease (GvHD) and other toxicities associated with T-cell therapies.
- Other names
- NKG2D-41BB-CD3z CAR-NKAENKG-2D-41BB-CD3z CAR-NKAENKG 2D-41BB-CD3z CAR-NKAENKG2D-CAR NKAE cellsNKG-2D-CAR NKAE cellsNKG 2D-CAR NKAE cellsNKG2D-CAR-NKAE cellsNKG-2D-CAR-NKAE cellsNKG 2D-CAR-NKAE cellsNKG2D-CAR transduced NKAE cellsNKG-2D-CAR transduced NKAE cellsNKG 2D-CAR transduced NKAE cells
Beyond the preview
Go deeper on NKG2D-41BB-CD3z CAR-NKAE cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NKG2D-41BB-CD3z CAR-NKAE cells.